Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal therapy of genotype-2 chronic hepatitis C: what's new?

Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2015

Bourlière Marc, Benali Souad, Ansaldi Christelle, Le Folgoc Gaelle, Riso Aurelie, Lecomte Laurence

Abstract excerpt

The standard of care (SOC) for the treatment of HCV genotype 2 (HCV-2) was pegylated interferon alpha plus ribavirin (PEG-IFN/RBV) at weight-based doses for a response-guided duration. The launches of sofosbuvir and daclatasvir in 2014 have resulted in new, better tolerated and shorter treatment. The combination of sofosbuvir and RBV for 12 weeks appears to be the new SOC in both European and American guidelines....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Prevalence

Share to Ribavirin

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Identifiers

PMID: 25529084
DOI: 10.1111/liv.12711

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal therapy of genotype-2 chronic hepatitis C: what's new?PMID 25529084Read ↗

How to optimize current treatment of genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

What's new in HCV genotype 2 treatment.Semantic proximity Read ↗

Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.Semantic proximity Read ↗

[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3].Semantic proximity Read ↗

Update on the treatment of hepatitis C genotypes 2-6.Semantic proximity Read ↗

Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.Semantic proximity Read ↗

Therapy for hepatitis C genotype 3: moving forward.Semantic proximity Read ↗

Treatment of hepatitis C: a systematic review.Semantic proximity Read ↗

Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.